PR Newswire Clinical TrialsOriginal article
Ribo Submits European Clinical Trial Application for Phase Ⅰ Study of INHBE-Targeting siRNA RBD3133
Phase 1RBD3133Positive
AI Analysis
Summary
Ribo announced successful submission of a Phase 1 Clinical Trial Application in the EU for RBD3133, an INHBE-targeting siRNA therapeutic. The filing marks progression of the candidate into human clinical evaluation.
Clinical Trial Data
Phase
Phase 1
Outcome Details
Clinical Trial Application submitted to EU
Importance:6/10
Sentiment:
0.60
siRNAINHBE-targetingEU clinical trialRare diseaseGene therapy
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 8, 2026 1:41 AM